news
Natural killer cell immunotherapy shows promise against melanoma
Researchers have shown that natural killer cell immunotherapy effectively treated mice harbouring human melanoma tumours.
List view / Grid view
Immunotherapy
article
The other end of the antibody: Fc biology and immunotherapy
Dr Björn Frendeus outlines how the growing biology surrounding the inhibitory Fc receptor FcγRIIb defines a target for improving existing and future antibody treatments.
news
Common antidepressant drugs fight cancer in mice, study shows
Monoamine oxidase inhibitors can block the function of a protein, helping T cells to effectively fight cancer, a study in mice has shown.
article
Off-the-shelf T-cell therapy from gene edited stem cells
Dr Jo Brewer outlines research into allogeneic products by gene editing stem cells, which has the potential to build a broad family of multiple immune cell types, including T-cell therapies.
news
Newly identified protein could become target for cancer immunotherapy
Researchers have found a protein that, when inhibited in mice with cancer, increased the response to immunotherapy.
article
Monitoring the potency of cell therapies using bioelectronic assays
Chimeric antigen receptor (CAR) T and natural killer (NK) therapies may become the future of cancer treatment. Dr Jim Ross explains how bioelectronic assays are a non-invasive, label-free approach built for real-time, dynamic assessment of cell therapy potency.
news
New mouse model could be used to develop better HIV treatments
A new pre-clinical mouse model could enable the study of HIV infection and the testing of cell therapies against the virus.
news
Natural killer cells and bispecific antibody target lymphoma tumours
In pre-clinical studies, researchers showed that cord blood-derived natural killer cells and a bispecific antibody eliminated lymphoma cells.
news
Single-cell map of lung cancer sheds light on tumour development
A spatial atlas of early-stage lung cancer has been compiled at single-cell resolution, revealing new therapeutic targets.
news
Team identifies paediatric acute myeloid leukaemia drug target
Researchers have found that the gene mesothelin can be targeted by new antibody-drug conjugates to treat acute myeloid leukaemia in children.
article
New developments in the research field of immuno-oncology
The exciting potential of immunotherapy for cancer treatment continues its exploration and here, Drug Target Review investigates three of the latest pre-clinical developments in immuno-oncology research.
news
Role of macrophages in blood flow regulation after tissue damage revealed
Researchers have shown in mice that macrophages play a role in controlling blood flow and healing following tissue damage.
news
Tumour cell vaccine strategy developed for neuroblastoma and melanoma
A combination of checkpoint and small molecule inhibitors showed success at targeting Myc oncogenes in mouse neuroblastoma and melanoma models.
article
Immunosurveillance and the importance of CD4 T cells in developing cancer vaccines
In this article, Dr Lien Lybaert describes how the innate and adaptive immune system work together to produce an effective and durable antitumour response. She explains why the best strategy for personalised cancer therapy is therefore to identify major histocompatibility (MHC) binding epitopes to cover the full antigenic repertoire of…
article
Glycolytic-pathway inhibition and CTLA-4 blockade to improve immuno-oncology
In this Q&A, Dr Taha Merghoub discusses how a combination of glycolytic-pathway inhibition and immune checkpoint blockade using anti-CTLA-4 in patients with highly glycolytic tumours could present a personalised approach for immuno-oncology.
